Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Alogliptin (Nesina) and sitagliptin (Januvia) are both medications used to treat Type 2 diabetes and belong to the same drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors. They help lower blood sugar levels by increasing insulin release and lowering the amount of sugar your body makes. However, there are some differences between the two medications. Alogliptin is typically taken at a dose of 6.25 mg to 25 mg once daily, while sitagliptin is taken at a dose of 25 mg to 100 mg once daily. Alogliptin is available as a lower-cost generic, but sitagliptin is only available as a brand name medication. Alogliptin may cause side effects like headaches and symptoms of the common cold, while sitagliptin can cause a runny nose and sore throat. Both medications can cause joint pain and have risks related to heart failure and pancreatitis.
Alogliptin (Nesina)
Januvia (sitagliptin)
Alogliptin (Nesina)
Januvia (sitagliptin)
Summary of Alogliptin vs. Januvia
Summary for DDP-4 inhibitor
Prescription only
Alogliptin (Nesina) is a medication that treats Type 2 diabetes. It's added to diet and exercise to help lower your blood sugar levels. But it isn't a first-choice treatment for this condition. Alogliptin (Nesina) is typically taken by mouth once a day. Some people may experience certain side effects, such as headaches or symptoms of the common cold (e.g., sore throat or runny nose), after starting this medication.
Summary for DDP-4 inhibitor
Prescription only
Januvia (sitagliptin) is a prescription medication that helps lower blood sugar in adults with Type 2 diabetes. It works best when you also follow a balanced diet and exercise regularly. It belongs to the drug class called dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins. Januvia (sitagliptin) comes as a tablet you take by mouth once a day. Side effects include stuffy or runny nose and headache. Januvia (sitagliptin) is a brand-name medication only; the generic version isn't available yet.